The Portfolio Committee on Basic Education Chairperson, Ms Joy Maimela, today welcomed the signing into law of the Basic Education Laws Amendment (BELA) Bill.

The BELA Bill was assented into law today by President Cyril Ramaphosa. However, the President put on hold clauses 4 and 5 of the Bill for three months in order to find solutions to those clauses. Should no solutions be found, the Bill will be implemented fully.

Ms Maimela said the legislation has been more than 11 years in the making and is in line with continuing the transformation agenda of the education sector.

Among other things, the Bill makes Grade R the new compulsory school-starting age; provides for penalties for parents who do not ensure that their children are in school; and confirms that corporal punishment is no longer allowed at schools, with penalties for those found guilty of such offences.

The Bill amplifies the corporal punishment definition and brings in the Criminal Procedure Act (CPA) definition because it is constantly used now in the Act and the Bill. The Act further expanded the powers of the courts in dealing with sentencing and penalties by adding that the courts’ discretion is best placed to decide such matters in accordance with the CPA, with regards to parents or guardians who disregard the requirement to ensure children are in school.

In terms of language policy, the amendment states that the governing body must submit the language policy of a public school and any amendment thereof to the head of department for approval. The language policy must also take into consideration the language needs of the broader community. “The committee notes that this relates to one of the clauses that the President put on hold for three months. We look forward to the engagement on this but continue to call for the full implementation of the Bill,” the Chairperson said.

In terms of the Bill, home education is allowed but must be regulated in terms of site visits that can happen at any place of choice, should the parents not agree to such visits at their homes. Furthermore, a report at the end of each phase will now be required by a qualified educator or assessor to prove the competency of the learner in that phase.

“The committee commends the President for signing into law this very progressive piece of legislation that will see the landscape of schooling in South Africa changing for the better. This is indeed what South Africa needs at this stage,” Ms Maimela said.

Distributed by APO Group on behalf of Republic of South Africa: The Parliament.

The Chairperson of the Portfolio Committee on Justice and Constitutional Development, Mr Xola Nqola, today welcomed the approval of the Legal Sector Code of the Broad-Based Black Economic Empowerment (B-BBEE) Act.

Mr Nqola said the Code will go a long way in transforming the sector and will do so speedily. He said drafting the Legal Sector Code started in the previous administration. “This process has paved the way for the legal sector to achieve its B-BBEE objectives and will lead to faster transformation of the sector, which has thus far been very unequal, especially in complex legal matters and state procurement,” he said.

The objectives of the Code, which was approved by the Minister of Trade, Industry and Competition, Mr Parks Tau, yesterday, include a target of 50% black representation and 25% black women ownership over five years, as well as management control in executive and board participation. The Code also targets 50% representation of black practitioners and 25% for black women practitioners, particularly as equity partners and associates.

“These targets will clearly drive transformation of the legal sector at a much faster pace than what has been happening up to now,” said Mr Nqola.

The Code is aimed at a skills development target of 3.5% expenditure on training programmes for black candidates. The aim is also to ensure training in specialised skills for black legal practitioners, candidate legal practitioners and black junior advocates within the designated categories: black women, black youth, black people with disabilities, and black people from rural areas. The Code also has a procurement target of 60% for the private sector, and a target of 80% is to be achieved through the specialised procurement scorecard applicable to the public sector.

Mr Nqola said this would ensure black practitioners have better opportunities to specialise in specialised areas of law when the state procures legal services from black legal entities. “This is a step in the right direction. Transformation in this sector has been too slow, leading to black practitioners being overlooked due to either lack of experience or exposure,” he said.

Distributed by APO Group on behalf of Republic of South Africa: The Parliament.

In coordination with Member States, the World Health Organization (WHO) and partners have established an access and allocation mechanism for mpox medical countermeasures including vaccines, treatments and diagnostic tests. The Access and Allocation Mechanism (AAM) will increase access to these tools for people at highest risk and ensure that the limited supplies are used effectively and equitably.   

This is part of the response to the public health emergency of international concern declared by WHO Director-General Dr Tedros Adhanom Ghebreyesus on 14 August 2024, following an upsurge of mpox in the Democratic Republic of the Congo and neighbouring countries. Fifteen countries in Africa have reported mpox this year. Recommendations issued on the advice of the International Health Regulations Emergency Committee asked States Parties to ensure “equitable access to safe, effective and quality-assured countermeasures for mpox.”  

“Alongside other public health interventions, vaccines, therapeutics and diagnostics are powerful tools for bringing the mpox outbreaks in Africa under control,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “The COVID-19 pandemic illustrated the need for international coordination to promote equitable access to these tools so they can be used most effectively where they are most needed. We urge countries with supplies of vaccines and other products to come forward with donations, to prevent infections, stop transmission and save lives.” 

The AAM was established as a part of the interim Medical Countermeasures Network (i-MCM-Net). The i-MCM-Net brings together partners from around the world, including UN and other international agencies, health organizations, civil society organizations, industry and private sector to build an effective ecosystem for the development, manufacturing, allocation and delivery of medical countermeasures. The network was endorsed by WHO Member States as a mechanism to operate in the interim, as negotiations continue towards a pandemic agreement. 

Along with WHO, the AAM for mpox includes members of the i-MCM-Net: the Africa Centres for Disease Control and Prevention, the Coalition for Epidemic Preparedness Innovations, the EU’s Health Emergency Preparedness and Response Authority, FIND, Gavi, the PAHO Revolving Fund, UNICEF, Unitaid and others. 

Over 3.6 million doses of vaccines have been pledged for the mpox response.  This includes 620 000 doses of the MVA-BN vaccine pledged to affected countries by the European Commission, Austria, Belgium, Croatia, Cyprus, France, Germany, Luxembourg, Malta, Poland, Spain, and the United States of America, as well as vaccine manufacturer Bavarian Nordic. Japan has pledged 3 million doses of the LC16 vaccine, the largest number of doses pledged so far.   

The recent surge in mpox cases, coupled with the limited availability of vaccines and other medical countermeasures, underscores the need for a collaborative and transparent process to distribute these critical resources fairly. The AAM is working to allocate the currently scarce supplies of vaccines and diagnostics for those at the highest risk of infection, including for vaccinating contacts of confirmed cases, and providing access to point of care diagnostics to countries with ongoing mpox outbreaks so that people who might be suspected cases can systematically be tested and cared for.  

The AAM will operate based on these guiding principles:  

Preventing illness and death: Prioritize vaccination and other tools to interrupt transmission for those at greatest risk to prevent illness and death.  
Mitigating inequity: Ensure equitable access to medical countermeasures for all people at risk, irrespective of socio-economic or demographic background.  
Ensuring transparency and flexibility: Establish and maintain clear and open communication about allocation decisions and be ready to adapt strategies as new data emerge or situations change.

“WHO and partners are supporting the government of the Democratic Republic of the Congo and other countries to implement an integrated approach to case detection, contact tracing, targeted vaccination, clinical and home care, infection prevention and control, community engagement and mobilization, and specialized logistical support,” said Dr Mike Ryan, Executive Director of WHO’s Health Emergencies Programme. “The AAM will provide a reliable pipeline of vaccines and other tools in order to ensure the success on the ground in interrupting transmission and reducing suffering.” 

Distributed by APO Group on behalf of World Health Organization (WHO).

The World Health Organization (WHO) has announced the MVA-BN vaccine as the first vaccine against mpox to be added to its prequalification list.

The prequalification approval is expected to facilitate timely and increased access to this vital product in communities with urgent need, to reduce transmission and help contain the outbreak. WHO’s assessment for prequalification is based on information submitted by the manufacturer, Bavarian Nordic A/S, and review by the European Medicines Agency, the regulatory agency of record for this vaccine.

“This first prequalification of a vaccine against mpox is an important step in our fight against the disease, both in the context of the current outbreaks in Africa, and in future,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “We now need urgent scale up in procurement, donations and rollout to ensure equitable access to vaccines where they are needed most, alongside other public health tools, to prevent infections, stop transmission and save lives.”

The MVA-BN vaccine can be administered in people over 18-years of age as a 2-dose injection given 4 weeks apart. After prior cold storage, the vaccine can be kept at 2–8°C for up to 8 weeks.

“The WHO prequalification of the MVA-BN vaccine will help accelerate ongoing procurement of the mpox vaccines by governments and international agencies such as Gavi and Unicef to help communities on the frontlines of the ongoing emergency in Africa and beyond,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. “The decision can also help national regulatory authorities to fast-track approvals, ultimately increasing access to quality-assured mpox vaccine products.”

The WHO Strategic Advisory Group of Experts (SAGE) on Immunization reviewed all available evidence and recommended the use of MVA-BN vaccine in the context of an mpox outbreak for persons at high risk of exposure. While MVA-BN is currently not licensed for persons under 18 years of age, this vaccine may be used “off-label” in infants, children and adolescents, and in pregnant and immunocompromised people. This means vaccine use is recommended in outbreak settings where the benefits of vaccination outweigh the potential risks.

WHO also recommends single-dose use in supply-constrained outbreak situations. WHO emphasizes the need to collect further data on vaccine safety and effectiveness in these circumstances.

Available data shows that a single-dose MVA-BN vaccine given before exposure has an estimated 76% effectiveness in protecting people against mpox, with the 2-dose schedule achieving an estimated 82% effectiveness. Vaccination after exposure is less effective than pre-exposure vaccination.

Good safety profile and vaccine performance has been consistently demonstrated in clinical studies, as well as in real-world use during the ongoing global outbreak since 2022. In light of the changing epidemiology and emergence of new virus strains, it remains important to collect as much data as possible on vaccine safety and effectiveness in different contexts.

Since the triggering of the emergency use listing for mpox vaccines by WHO Director-General on 7 August 2024, WHO has conducted product and programmatic suitability assessments of MVA-BN vaccine.

“The findings of the assessments are particularly relevant in the context of the declaration of a public health emergency of international concern (PHEIC) related to the upsurge of mpox in Africa,” said Dr Rogerio Gaspar, WHO Director for Regulation and Prequalification. “We are progressing with prequalification and emergency use listing procedures with manufacturers of two other mpox vaccines: LC-16 and ACAM2000. We have also received 6 expressions of interest for mpox diagnostic products for emergency use listing so far.”

The escalating mpox outbreak in the Democratic Republic of the Congo and other countries was declared a PHEIC by the WHO Director-General on 14 August 2024. 

Over 120 countries have confirmed more than 103 000 cases of mpox since the onset of the global outbreak in 2022. In 2024 alone, there were 25 237 suspected and confirmed cases and 723 deaths from different outbreaks in 14 countries of the African Region (based on data from 8 September 2024).

Distributed by APO Group on behalf of World Health Organization (WHO).